Company Overview of Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology. The company’s lead drug candidate includes IMO-8400, which is in Phase 1/2 clinical trials for the treatment of Waldenström’s Macroglobulinemia, diffuse large B-cell lymphoma, and Duchenne muscular dystrophy, as well as in Phase 2 clinical trial for the treatment of dermatomyositis. Its p...
167 Sidney Street
Cambridge, MA 02139
Founded in 1989
Key Executives for Idera Pharmaceuticals, Inc.
Chief Executive Officer and Director
Total Annual Compensation: $50.0K
Chief Financial Officer, Senior Vice President of Operations, Treasurer and Secretary
Total Annual Compensation: $425.9K
President of Research and Director
Total Annual Compensation: $856.4K
Compensation as of Fiscal Year 2014.
Idera Pharmaceuticals, Inc. Key Developments
Idera Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse B-Cell Lymphoma
Apr 1 15
Idera Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, for the treatment of diffuse large B-cell lymphoma (DLBCL). Idera is currently conducting a clinical trial of IMO-8400 in patients with relapsed or refractory DLBCL harboring MYD88 L265P oncogenic mutation. Preclinical studies have shown that in B-cell lymphomas characterized by the MYD88 L265P oncogenic mutation, including DLBCL, TLR signaling is over-activated, thereby enabling tumor cell survival and proliferation. As a TLR antagonist, IMO-8400 inhibits TLR signaling. The objectives of the trial are to evaluate the compound's safety, tolerability and clinical activity. The protocol includes three dose-escalation cohorts of IMO-8400 administered subcutaneously.
Idera Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 01:40 PM
Mar 25 15
Idera Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 01:40 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Vincent J. Milano, Chief Executive Officer and Director.
Idera Pharmaceuticals, Inc. Announces Resignation of Louis Brenner as Senior Vice President and Chief Medical Officer, Effective April 3, 2015
Mar 23 15
On March 17, 2015, Louis Brenner, M.D. resigned his positions as Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc. to accept a new role as the Chief Operating Officer of a privately-held biotechnology company. This change will become effective April 3, 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|